Among the antidepressant drugs included in this study, treatment with citalopram was probably the only optimal intervention, when considering the improvement from baseline to the end of the intervention, and there was not a statistically significant difference in safety when compared with a placebo treatment.
Cannabis Medicines Appear Broadly Tolerated in Adults Over 50, But Key Uncertainties Remain
Although cannabinoid-based medications were generally safe and acceptable to adults aged over 50 years, these estimates are limited by the lack of a control condition and considerable heterogeneity. Nevertheless, they complement and are consistent with comparable evidence from randomised controlled trials.
Cannabis Medicines Cause Dose-Dependent Side Effects in Older Adults, Meta-Analysis Finds
THC dose-dependently increased the incidence of dry mouth, dizziness/lightheadedness, mobility/balance/coordination difficulties, dissociative/thinking/perception problems and somnolence/drowsiness.
Improving definitions and innovations for identification and prevention of postoperative opioid-induced respiratory depression (OIRD): Proceedings of the International Consensus Conference.
CED Clinical Relevance #58Monitored Relevance Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch | CED Clinic PainOpioidsSurgerySafetyMultimodal JournalJournal of clinical anesthesiaStudy TypeClinical StudyPopulationHuman participants Why This MattersPostoperative opioid-induced respiratory depression remains a...
Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms.
Appropriate treatment of muscle spasticity and spasms is important as these conditions may significantly impair patients’ quality of life. Conventional pharm…
Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.
The French National Agency for Medicines and Health Products Safety implemented in 2021 a nationwide experimentation for medical cannabis (MC), designed to a…
CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The incidence of serious adverse events is probably increased with CBD 20 mg/kg/day (RR 2.30; 95% CI 1.36–3.89, moderate certainty).
Association of Multimodal Cannabis Use with Adverse Events among Adolescents and Young Adults.
The ways cannabis is consumed, or modes of use, have increased and diversified in recent years, especially among young people. Associations of multimodal can…
Can CBD Cause Gynaecomastia? Evidence, Hormones, and Safe Use – Bolt Pharmacy
✦ New CED Clinical Relevance #60Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Endocrine EffectsCbdAdverse EventsMale HealthDrug Safety Why This MattersGynecomastia concerns with CBD could influence prescribing...
Safety of cannabidiol versus placebo in healthy population: a systematic review and meta-analysis.
Cannabidiol (CBD) has gained significant attention for its potential therapeutic benefits, but its safety profile in healthy populations remains underexplore…